Sagimet Biosciences Inc. Stock Price, News & Analysis

Sagimet Biosciences (Nasdaq: SGMT) reported Q3 2025 corporate updates and financials on November 13, 2025. Key clinical milestones include an ongoing Phase 1 PK trial of a once-daily combination of denifanstat and resmetirom (≈40 healthy adults) with topline data expected in 1H 2026, and an ongoing first-in-human Phase 1 trial of FASN inhibitor TVB-3567 for acne. Partner Ascletis completed a pre-NDA consultation with China’s NMPA and plans an NDA submission for denifanstat for moderate-to-severe acne after a 480-patient Phase 3 trial that met all efficacy endpoints. Financials: $125.5M cash and marketable securities; nine-month net loss $41.5M.

Sagimet Biosciences (Nasdaq: SGMT) presented two posters at AASLD The Liver Meeting® 2025 on November 7-11, 2025 reporting secondary analyses of the Phase 2b FASCINATE-2 trial for denifanstat.

Key findings: in AI-defined qFibrosis stage 4 (qF4) patients, denifanstat showed ≥1 qFibrosis stage regression in 85% (11/13) vs 33% (1/3) for placebo; in CRN-scored F3 patients, ≥2-stage fibrosis improvement was 34% (16/47) vs 4% (1/23) placebo (p=0.0065). Multiple noninvasive biomarkers fell substantially vs placebo at week 52 (FibroScan -29% vs +26%, FAST -45% vs +9%, MRI-PDFF -34% vs +14%, ALT -43%, AST -37%).

Sagimet (Nasdaq: SGMT) reported that denifanstat, a once-daily oral 50 mg FASN inhibitor, met all primary and secondary endpoints versus placebo in a Phase 3 randomized, double-blind, placebo-controlled trial in China enrolling 480 patients with moderate-to-severe acne (IGA 3–4) treated for 12 weeks. At Week 12, treatment success rates were more than double placebo with marked reductions in inflammatory and non-inflammatory lesions. Denifanstat was generally well tolerated. Ascletis completed a pre-NDA consultation with China NMPA and plans to submit an NDA soon. Trial data will be presented at the 2025 Fall Clinical Dermatology Conference (Oct 24–26) in Las Vegas.

Sagimet Biosciences (Nasdaq: SGMT) said management will participate in three investor conferences in Oct–Nov 2025: the H.C. Wainwright Liver Disease Virtual Conference on October 21–22 (fireside chat available starting October 21 at 7:00 AM ET), the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10 (fireside chat at 11:30 AM ET), and the UBS Global Healthcare Conference in Palm Beach on November 11.

Fireside chats from H.C. Wainwright and Guggenheim will be posted in the Investors & Media section of Sagimet’s website and archived for 90 days after each live event.

Ascletis (HKEX:1672) completed a pre-NDA consultation with China NMPA for denifanstat (ASC40) for moderate-to-severe acne vulgaris, initiated in June 2025 and completed in October 2025, and plans to submit an NDA soon.

Ascletis completed Phase II (NCT05104125) and Phase III (NCT06192264) studies; the Phase III met all primary, key secondary and secondary efficacy endpoints (ITT) and showed statistically significant improvement versus placebo. Denifanstat demonstrated a favorable safety and tolerability profile: all related TEAEs were Grade 1–2, with no related Grade 3–4 TEAEs, SAEs, permanent discontinuations, or withdrawals. Phase III results were presented at EADV Congress on Sept 17, 2025. Ascletis holds exclusive Greater China rights via license from Sagimet (Nasdaq: SGMT).

Sagimet Biosciences (Nasdaq: SGMT) will present Phase 2b FASCINATE-2 secondary analyses showing that denifanstat produced a ≥2-stage fibrosis improvement in F3 MASH patients and improved fibrosis and biomarkers in qFibrosis stage 4 MASH patients.

The data, described as showing a robust anti-fibrotic effect by conventional and AI-based digital pathology and improved non-invasive test biomarkers in a qF4 subpopulation, was selected as a Poster of Distinction for AASLD—The Liver Meeting 2025 on November 10, 2025 in Washington, DC; presenting author is Rohit Loomba, M.D., M.H.Sc.

Sagimet Biosciences (Nasdaq: SGMT) has initiated dosing in a Phase 1 pharmacokinetic (PK) trial combining their oral FASN inhibitor denifanstat with THR-β agonist resmetirom. The trial will enroll approximately 40 healthy adult participants across 2 cohorts to evaluate drug interactions, safety, and tolerability.

The study aims to inform optimal dosing for a future Phase 2 combination trial in F4 MASH (metabolic dysfunction-associated steatohepatitis) patients. Topline data is expected in H1 2026. The combination therapy builds on promising preclinical data presented at EASL 2024, which demonstrated synergistic effects on liver disease markers when combining a FASN inhibitor with resmetirom.

Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, will participate in a panel discussion at Fierce Biotech Week in Boston, MA from October 7-9, 2025. The company's Senior Vice President of Research and Development, Dr. Marie O'Farrell, will join a panel focused on AI/Machine Learning applications in biotechnology.

The presentation, scheduled for October 9, 2025, at 11:15 AM ET, will highlight Sagimet's use of AI-based digital pathology platforms in clinical trials, particularly for analyzing liver biopsies in metabolic dysfunction associated steatohepatitis (MASH) drug development.

Ascletis presented successful Phase III clinical trial results for denifanstat (ASC40), a first-in-class FASN inhibitor for acne treatment, at EADV Congress 2025. The trial, involving 480 patients with moderate to severe acne vulgaris, demonstrated that denifanstat met all primary, key secondary, and secondary efficacy endpoints.

Key achievements include 33.17% treatment success versus 14.58% for placebo, 57.38% reduction in total lesion count, and 63.45% reduction in inflammatory lesions. The drug showed a favorable safety profile, with TEAEs comparable to placebo (58.6% vs 56.3%). Ascletis plans to submit an NDA to China's NMPA following encouraging pre-NDA consultation feedback.